- Home
- NRC vs TRDA Comparison
NRC vs TRDA Comparison
Compare NRC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- TRDA
- Stock Information
- Founded
- NRC 1981
- TRDA 2016
- Country
- NRC United States
- TRDA United States
- Employees
- NRC N/A
- TRDA N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- TRDA Health Care
- Exchange
- NRC Nasdaq
- TRDA Nasdaq
- Market Cap
- NRC 278.8M
- TRDA 264.4M
- IPO Year
- NRC N/A
- TRDA 2021
- Fundamental
- Price
- NRC $16.11
- TRDA $8.49
- Analyst Decision
- NRC
- TRDA Strong Buy
- Analyst Count
- NRC 0
- TRDA 2
- Target Price
- NRC N/A
- TRDA $24.50
- AVG Volume (30 Days)
- NRC 102.3K
- TRDA 276.9K
- Earning Date
- NRC 10-27-2025
- TRDA 11-06-2025
- Dividend Yield
- NRC 4.20%
- TRDA N/A
- EPS Growth
- NRC N/A
- TRDA N/A
- EPS
- NRC 0.71
- TRDA N/A
- Revenue
- NRC $139,102,000.00
- TRDA $61,520,000.00
- Revenue This Year
- NRC N/A
- TRDA N/A
- Revenue Next Year
- NRC N/A
- TRDA N/A
- P/E Ratio
- NRC $21.45
- TRDA N/A
- Revenue Growth
- NRC N/A
- TRDA N/A
- 52 Week Low
- NRC $9.76
- TRDA $4.93
- 52 Week High
- NRC $20.11
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- NRC 73.66
- TRDA 70.59
- Support Level
- NRC $14.75
- TRDA $6.09
- Resistance Level
- NRC $14.18
- TRDA $9.15
- Average True Range (ATR)
- NRC 0.74
- TRDA 0.63
- MACD
- NRC 0.30
- TRDA 0.16
- Stochastic Oscillator
- NRC 95.77
- TRDA 77.78
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.